/MRKR
MRKR Stock - Marker Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.28+1.59%
+$0.02 (+1.59%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.72
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.66
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.41
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MRKR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.27 – $1.29
TARGET (TP)$1.47
STOP LOSS$1.18
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.35
52W High$4.07
52W Low$0.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.59M | $3.31M | $3.51M | $1.24M | $466,785 |
| Gross Profit | $-6,876,765 | $-7,105,656 | $-8,454,884 | $-1,920,928 | $-18,414,000 |
| Gross Margin | -104.3% | -214.6% | -240.6% | -154.7% | -3944.9% |
| Operating Income | $-11,118,372 | $-14,581,378 | $-19,791,004 | $-39,477,995 | $-28,886,000 |
| Net Income | $-10,731,315 | $-8,236,814 | $-29,930,694 | $-41,878,871 | $-28,706,000 |
| Net Margin | -162.8% | -248.8% | -851.9% | -3372.7% | -6149.7% |
| EPS | $-1.19 | $-1.93 | $-3.58 | $-5.47 | $-6.10 |
Company Overview
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$8
Average Target
↑ 525.0% Upside
Now
$8
Low
$8
Average
$8
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 5th 2025 | Canaccord Genuity | Initiation | Buy | $8 |
Earnings History & Surprises
MRKRBeat Rate
68%
Last 19 quarters
Avg Surprise
+17.9%
EPS vs Estimate
Beats / Misses
13/4
2 met exactly
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
+52.0%
$-0.48vs$-1.00
Q2 24
-8.0%
$-0.27vs$-0.25
Q3 24
+41.9%
$-0.25vs$-0.43
Q4 24
+33.3%
$-0.26vs$-0.39
Q1 25
-13.5%
$-0.42vs$-0.37
Q2 25
+59.1%
$-0.27vs$-0.66
Q3 25
+47.3%
$-0.29vs$-0.55
Q4 25
+82.6%
$-0.12vs$-0.69
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.21 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.69 | $-0.12 | +82.6% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.55 | $-0.29 | +47.3% | ✓ BEAT |
Q2 2025 | May 21, 2025 | $-0.66 | $-0.27 | +59.1% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.37 | $-0.42 | -13.5% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.39 | $-0.26 | +33.3% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.43 | $-0.25 | +41.9% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.25 | $-0.27 | -8.0% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | $-1.00 | $-0.48 | +52.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.90 | $-0.34 | +62.2% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.80 | $-0.47 | +41.3% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $0.80 | $-0.57 | -171.3% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-1.00 | $-0.48 | +52.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-1.30 | $-0.80 | +38.5% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.30 | $-1.10 | +15.4% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-1.30 | $-1.20 | +7.7% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-1.20 | $-1.20 | 0.0% | = MET |
Q4 2021 | Nov 10, 2021 | $-1.30 | $-1.20 | +7.7% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-1.20 | $-1.30 | -8.3% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-1.60 | $-1.60 | 0.0% | = MET |
Latest News
HC Wainwright & Co. Initiates Coverage On Marker Therapeutics with Buy Rating, Announces Price Target of $10
📈 PositiveBenzinga•Dec 8, 2025, 02:44 PM
Marker Therapeutics Q3 EPS $(0.12) Beats $(0.47) Estimate, Sales $1.233M Beat $723.000K Estimate
📈 PositiveBenzinga•Nov 13, 2025, 10:31 PM
Marker Therapeutics To Present Data From Phase 1 APOLLO Study Investigating MT-601 In Patients With Relapsed B Cell Lymphomas At ASH 2025
➖ NeutralBenzinga•Nov 3, 2025, 02:30 PM
Marker Therapeutics Announces First Patient Treated In OTS Program, With Encouraging Preliminary Safety Data
📈 PositiveBenzinga•Oct 6, 2025, 11:33 AM
Marker Therapeutics shares are trading higher after the company reported results from its Phase 1 APOLLO study of MT-601.
📈 PositiveBenzinga•Aug 26, 2025, 12:50 PM
Marker Therapeutics Reports 66% ORR And 50% CR In NHL Patients From Phase 1 APOLLO Study Of MT-601, Shows Favorable Safety Profile With No DLTs, Prepares Dose Expansion In Relapsed DLBCL
📈 PositiveBenzinga•Aug 26, 2025, 11:03 AM
Frequently Asked Questions about MRKR
What is MRKR's current stock price?
Marker Therapeutics, Inc. (MRKR) is currently trading at $1.28 per share. The stock has moved +1.59% today.
What is the analyst price target for MRKR?
No analyst price targets are currently available for this stock.
What sector is Marker Therapeutics, Inc. in?
Marker Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MRKR's market cap?
Marker Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does MRKR pay dividends?
No, Marker Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
BOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
CLRB
Cellectar Biosciences, Inc.
$2.68
Mkt Cap: $0.0B
COCP
Cocrystal Pharma, Inc.
$0.99
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
GLTO
Galecto, Inc.
$27.17
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
MBIO
Mustang Bio, Inc.
$1.09
Mkt Cap: $0.0B
PHIO
Phio Pharmaceuticals Corp.
$1.07
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
Explore stocks similar to MRKR for comparison